Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PET scans reveal how gut hormones control sugar use

NCT ID NCT07398300

Knowledge-focused Sponsor: Rigshospitalet, Denmark Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study uses advanced full-body PET scans to see how natural gut hormones (GIP and GLP-1) affect how the body takes up sugar and blood flow. It includes healthy adults and people with type 2 diabetes. The goal is to better understand how these hormones work after eating, which may guide future treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

23 to 64 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Sub-study 1 (Healthy individuals): * Age 23-50 years * BMI 20.0-26.9 kg/m² * HbA1c \< 42 mmol/mol * Able to provide informed consent Sub-study 2 - Participants with Type 2 Diabetes: * Age 23-60 years * Diagnosed with type 2 diabetes for ≥3 months * HbA1c \> 53 mmol/mol * Treatment with metformin only * Able to provide informed consent Sub-study 2 - Healthy control participants: * Age 23-64 years * HbA1c \< 42 mmol/mol * Able to provide informed consent Exclusion Criteria (applies to all participants unless otherwise specified): * Anaemia (haemoglobin below normal range) * ALT \> 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder * Kidney disease (creatinine above normal range) * Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery) * For Sub-study 1: Type 1 or type 2 diabetes or HbA1c ≥ 42 mmol/mol * Use of glucose-lowering medications other than metformin (Sub-study 2 only) * Chronic obstructive pulmonary disease (Sub-study 2 only) * Regular tobacco smoking or use of nicotine-containing products * Claustrophobia * Pregnancy, breastfeeding, or intention to become pregnant during the study period * Initiation of special diets, major lifestyle changes, or weight loss \> 5% within 3 months prior to or during the study * Any medication or physical/psychological condition that may interfere with participation (per investigator judgement) * Inability to speak or read Danish

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healhty are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healhty Type 2 diabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Copenhagen University Hospital - Rigshospitalet

    RECRUITING

    Copenhagen, 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.